Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance)
      QxMD      Google Scholar   
Citation:
Cancer Epidemiol Biomarkers Prev vol 30 (2) 404-11
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
10
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
PPP
Sec. Committees:
   
Pharmas:
Genentech, Sanofi, Pfizer, Eli Lilly and Company  
Grants:
U10CA180821, U10CA180882, U24CA196171, R01CA176272, UG1CA233180, UG1CA233339, UG1CA189858, T32 CA094880, K05 CA152715  
Corr. Author:
 
Authors:
                                     
Networks:
LAPS-MN026, LAPS-OH007   
Study
Alliance-A151904
Multiple Studies, or Legacy Studies in Alliance Study:
NCCTG-N0147
Phases:
N/A, 3
Keywords: